2-biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]phenyl}-propionic acid methyl ester | 501030-46-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]phenyl}-propionic acid methyl ester
• 英文别名: Methyl 3-[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl]-2-(3-phenylphenyl)propanoate
• CAS: 501030-46-2
• 化学式: C₃₅H₃₃NO₃
• 分子量: 515.652
• InChiKey: ZDUNLAYLPXIXOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]phenyl}-propionic acid methyl ester 以69%的产率得到2-Biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-propionic acid
  参考文献：
  名称：

  Antidiabetic agents

  摘要：

  本发明提供了式(I)的化合物： 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值，以及药用可接受的盐，这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物，制备式I化合物的方法，以及用于制备式I化合物的中间体。

  公开号：

  US20030171377A1
• 作为产物：
  描述：

  2-biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]phenyl}-propionic acid methyl ester 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以91%的产率得到2-biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]phenyl}-propionic acid methyl ester
  参考文献：
  名称：

  Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies

  摘要：

  A new series of alpha-aryl or alpha-heteroarylphenyl propanoic acid derivatives was synthesized that incorporate acetylene-, ethylene-, propyl-, or nitrogen-derived linkers as a replacement of the commonly used ether moiety that joins the central phenyl ring with the lipophilic tail. The effect of these modi. cations in the binding and activation of PPAR alpha and PPAR gamma was first evaluated in vitro. Compounds possessing suitable profiles were then evaluated in the ob/ob mouse model of type 2 diabetes. The propylene derivative 40 and the propyl derivative 53 demonstrated robust plasma glucose lowering activity in this model. Compound 53 was also evaluated in male Zucker diabetic fatty rats and was found to achieve normalization of glucose, triglycerides, and insulin levels. An X-ray crystal structure of the complex of 53 with the PPAR gamma-ligand-binding domain was obtained and discussed in this report. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.03.043

文献信息

• Oral antidiabetic agents
  申请人：Warner-Lambert Company LLC

  公开号：EP1577305A1

  公开（公告）日：2005-09-21

  The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein:    A is    X is CH2-CH2-O or -CH2CH2CH2-;    Q is    Y is CH2;    Z is absent;    B is H;    D is H, and E is CO2H; that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

  本发明提供了式 (I) 的化合物 或其药学上可接受的盐，其中 A 是 X是CH2- -O或- -； Q 是 Y 是 Z 不存在； B 是 H； D 是 H、 和 E 是 CO2H； 可用作抗糖尿病药物。还公开了包含式（I）化合物的药物组合物。
• ORAL ANTIDIABETIC AGENTS
  申请人：Warner-Lambert Company LLC

  公开号：EP1423363A1

  公开（公告）日：2004-06-02
• [EN] ORAL ANTIDIABETIC AGENTS<br/>[FR] AGENTS ANTIDIABETIQUES ORAUX
  申请人：WARNER LAMBERT CO

  公开号：WO2003018553A1

  公开（公告）日：2003-03-06

  The present invention provides compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, process for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.